Beyond Dopamine: Glutamate as a Target in Schizophrenia
An interesting review in ISRN Pharmacology, a peer-reviewed, open access journal, describes that for the last 60 years, antipsychotic pharmacology targeting antagonism of dopamine (DA) D2 receptors have been the primary treatment choice for schizophrenia. The clinical improvement seen …